Scarica l'app Stockscreener
102.92
1.33%
1.35
Dopo l'orario di chiusura:
102.90
-0.02
-0.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$101.57
Aprire:
$101.845
Volume 24 ore:
3.53M
Relative Volume:
1.76
Capitalizzazione di mercato:
$20.10B
Reddito:
$4.58B
Utile/perdita netta:
$870.87M
Rapporto P/E:
23.40
EPS:
4.3988
Flusso di cassa netto:
$945.58M
1 W Prestazione:
+12.30%
1M Prestazione:
+18.50%
6M Prestazione:
+64.59%
1 anno Prestazione:
+35.87%
Intervallo 1D:
$100.02
$103.86
Intervallo di 1 settimana:
$88.20
$103.86
Portata 52W:
$53.56
$103.86
Incyte Corp Stock (INCY) Company Profile
Nome
Incyte Corp
Settore
Industria
Telefono
(302) 498-6700
Indirizzo
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Confronta INCY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
102.92 | 19.94B | 4.58B | 870.87M | 945.58M | 4.3988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Iniziato | Barclays | Overweight |
| 2025-06-16 | Aggiornamento | Stifel | Hold → Buy |
| 2025-03-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Iniziato | UBS | Neutral |
| 2024-10-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-01 | Iniziato | Wolfe Research | Outperform |
| 2024-09-18 | Downgrade | Truist | Buy → Hold |
| 2024-07-02 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Iniziato | Deutsche Bank | Hold |
| 2024-04-23 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Iniziato | Jefferies | Buy |
| 2024-02-14 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-11-21 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-25 | Iniziato | Citigroup | Buy |
| 2023-05-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Iniziato | Piper Sandler | Overweight |
| 2022-08-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-07-28 | Iniziato | Wells Fargo | Equal Weight |
| 2022-02-09 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-07-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Iniziato | Truist | Buy |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-06-16 | Iniziato | The Benchmark Company | Hold |
| 2020-05-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Ripresa | William Blair | Outperform |
| 2020-03-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Ripresa | BofA/Merrill | Neutral |
| 2020-01-03 | Reiterato | BMO Capital Markets | Market Perform |
| 2020-01-03 | Downgrade | Mizuho | Buy → Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-10-03 | Iniziato | Mizuho | Buy |
| 2019-09-12 | Iniziato | BMO Capital Markets | Market Perform |
| 2019-09-05 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Iniziato | Credit Suisse | Neutral |
| 2019-05-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Iniziato | Stifel | Hold |
| 2019-04-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Aggiornamento | William Blair | Mkt Perform → Outperform |
Mostra tutto
Incyte Corp Borsa (INCY) Ultime notizie
Incyte (INCY) Receives Raised Price Target from Piper Sandler | - GuruFocus
Incyte (NASDAQ:INCY) Hits New 52-Week High After Analyst Upgrade - MarketBeat
Incyte (INCY) Secures $935M Deal with Prelude Therapeutics for J - GuruFocus
Incyte (NASDAQ:INCY) Upgraded by Guggenheim to Buy Rating - MarketBeat
Incyte (INCY) Secures Option for JAK2V617F Program in $910M Deal - GuruFocus
Incyte (INCY) Secures Exclusive Option on JAK2V617F Program - GuruFocus
Prelude Therapeutics stock climbs after exclusive JAK2 option deal with Incyte - Investing.com UK
Prelude Therapeutics Announces Strategic Updates: Prioritizes JAK2V617F and KAT6A Programs, Pauses SMARCA2 Development and Secures $60 Million from Incyte Option Agreement - Quiver Quantitative
Hussman Strategic Advisors Inc. Boosts Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte (INCY) Extends Climb, Hits New High on Bullish Coverage - Insider Monkey
The 5 Most Interesting Analyst Questions From Incyte’s Q3 Earnings Call - Barchart.com
Incyte Corporation (INCY) Stock Forecasts - Yahoo! Finance Canada
Incyte Corporation (INCY) Stock forecasts - Yahoo! Finance UK
Is Incyte Corporation (ICY) stock dividend growth reliableJuly 2025 Sector Moves & Community Consensus Trade Alerts - newser.com
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte stock jumps on promising cancer data - Investing.com
Is It Too Late to Ride INCY’s Upsurge? - timothysykes.com
Incyte (INCY) Shares Rise Following Promising Myelofibrosis Data - GuruFocus
Incyte (INCY) Upgraded to Buy by Guggenheim, Price Target Set at $125 | INCY Stock News - GuruFocus
INCY: Promising Myelofibrosis Treatment Bolsters Incyte's Prospe - GuruFocus
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting - Yahoo Finance
Is Incyte Corporation building a consolidation basePortfolio Value Report & AI Enhanced Trading Alerts - newser.com
What’s next for Incyte Corporation stock priceEarnings Overview Summary & Weekly Breakout Stock Alerts - newser.com
Will Incyte Corporation (ICY) stock return to pre crash levelsEarnings Summary Report & Free Real-Time Market Sentiment Alerts - newser.com
Incyte Corporation $INCY Shares Sold by South Dakota Investment Council - MarketBeat
Will Incyte Corporation stock see PE expansionMarket Activity Summary & Expert Verified Stock Movement Alerts - newser.com
Bessemer Group Inc. Reduces Stock Holdings in Incyte Corporation $INCY - MarketBeat
Key metrics from Incyte Corporation’s quarterly dataJuly 2025 Opening Moves & Safe Entry Point Alerts - newser.com
Incyte Corp (INCY) Stock Price, Trades & News - GuruFocus
Can Incyte Corporation stock hit record highs againPortfolio Update Summary & AI Forecast for Swing Trade Picks - newser.com
Incyte (NASDAQ:INCY) Raised to "Strong-Buy" at Wall Street Zen - MarketBeat
Pharmaceutical Stocks To Keep An Eye OnOctober 28th - MarketBeat
How Incyte Corporation stock performs in rising dollar environmentJuly 2025 Recap & AI Based Trade Execution Alerts - newser.com
Incyte Falls After Hiked 2025 Outlook Misses Wall Street's Bullish Views - MSN
Incyte to Present at Upcoming November 2025 Investor Conferences - BioSpace
Can Incyte Corporation (ICY) stock attract analyst upgradesQuarterly Market Summary & Real-Time Volume Analysis Alerts - newser.com
How Incyte Corporation stock responds to policy changesJuly 2025 Institutional & Real-Time Chart Pattern Alerts - newser.com
Is Incyte Corporation (ICY) stock undervalued by metricsBull Run & Free Expert Approved Momentum Trade Ideas - newser.com
Decoding Incyte Corp (INCY): A Strategic SWOT Insight - GuruFocus
Incyte Corp (INCY) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Incyte Corp (INCY) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... - Yahoo Finance
Incyte's (INCY) Hold Rating Reiterated at Truist Financial - MarketBeat
Incyte (INCY) Gains Exclusive Distribution Rights for Tafasitama - GuruFocus
Incyte to Present at Upcoming Investor Conferences - Yahoo Finance
Transcend Capital Advisors LLC Makes New $437,000 Investment in Incyte Corporation $INCY - MarketBeat
INCY (Incyte) 1-Year ROIIC % : 240.16% (As of Sep. 2025) - GuruFocus
Multi asset correlation models including Incyte CorporationMarket Risk Report & Fast Gain Stock Trading Tips - newser.com
Can Incyte Corporation stock deliver sustainable ROELayoff News & Safe Entry Point Alerts - newser.com
Incyte Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
RBC Capital Raises Incyte (INCY) Price Target to $84 | INCY Stoc - GuruFocus
Incyte (INCY) Rating Reiterated and Price Target Raised by Truis - GuruFocus
Incyte Corp Azioni (INCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.17%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):